← All Estrella Immunopharma, INC filings

Estrella Immunopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ESLA
Estrella Immunopharma, INC
10-K/A: Estrella Immunopharma Files 10-K/A for Governance Update
Estrella Immunopharma, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.
NASDAQ
ESLA
Estrella Immunopharma, INC
10-KT: Estrella Immunopharma Reports Financial Results for Six-Month Transition Period Ended December 31, 2024
Estrella Immunopharma details its financial performance for the six-month transition period ending December 31, 2024, highlighting ongoing clinical trials and strategic collaborations.
NASDAQ
ESLA
Estrella Immunopharma, INC
10-K/A: Estrella Immunopharma Files Amended 10-K to Include Omitted Information
Estrella Immunopharma has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.
NASDAQ
ESLA
Estrella Immunopharma, INC
10-K: Estrella Immunopharma Details Capital Structure and Regulatory Landscape in 10-K Filing
Estrella Immunopharma's 10-K filing outlines its capital structure, stock details, and regulatory environment, including its T-cell therapy development and strategic collaborations.